HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress
Provided By GlobeNewswire
Last update: May 8, 2025
$159.5 million of cash, cash equivalents and marketable securities as of March 31, 2025
The company is exploring the potential for continued development of its norovirus vaccine candidates in
adults as well as business development related activities and other strategic alternatives
